Bank Of Montreal Rigel Pharmaceuticals Inc Transaction History

Bank Of Montreal

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$0.72 - $1.56 $7,719 - $16,724	10,721 New	10,721 $15,000
Q2 2023 Aug 02, 2023	SELL	$1.12 - $1.82 $1,074 - $1,745	-959 Reduced 8.69%	10,073 $12,000
Q1 2023 Jun 13, 2024	BUY	$1.25 - $2.0 $22,740 - $36,384	18,192 New	18,192 $24,000
Q4 2022 Feb 01, 2023	BUY	$0.67 - $11.9 $400 - $7,116	598 Added 5.73%	11,032 $16,000
Q3 2022 Nov 10, 2022	BUY	$1.1 - $12.2 $183 - $2,037	167 Added 1.63%	10,434 $17,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $484 - $2,306	-723 Reduced 6.58%	10,267 $12,000
Q1 2022 May 12, 2022	SELL	$2.22 - $3.45 $9,392 - $14,596	-4,231 Reduced 27.8%	10,990 $35,000
Q4 2021 Feb 11, 2022	SELL	$2.36 - $3.57 $719,018 - $1.09 Million	-304,669 Reduced 95.24%	15,221 $41,000
Q3 2021 Nov 12, 2021	SELL	$3.5 - $4.5 $43,025 - $55,318	-12,293 Reduced 3.7%	319,890 $1.28 Million
Q2 2021 Aug 12, 2021	BUY	$3.09 - $4.54 $1.03 Million - $1.51 Million	332,183 New	332,183 $1.51 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.